Global Scans · test · Weekly Summary

• [New] The amount of data available in neurology and neuroscience is rising exponentially: the footprint of the data landscape was estimated at 4.4 zettabytes in 2015 and is projected to exceed 75 ZB in 2025. Nature
• The pipeline breadth is impressive - 19 NMEs by 2030 spanning oncology, neuroscience, cardiometabolic, immunology, and gene therapy. SyneticX
• With a massive pipeline in neuroscience, specifically Alzheimer's treatments, many analysts predict they will climb several spots in the pharmaceutical industry rankings by 2030. Global Healthcare Magazine
• As the experts in brain health, neurologists will ask lawmakers to maintain strong federal support for neuroscience research, including the National Institutes of Health Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative. EurekAlert!
• By 2035, advancements in quantum computing and neuroscience will converge to create the first rudimentary forms of quantum consciousness. Ian Khan, FutureSHIFT Experience Keynote & Workshop -
• Large language models, a type of AI that analyses text, can predict the results of proposed neuroscience studies more accurately than human experts, finds a new study led by UCL researchers. UCL News
• Pure-play psychedelic developers offer asymmetric upside tied to discrete clinical and regulatory inflection points, while larger neuroscience companies provide a more measured way to participate in innovation with lower binary risk. Gainify
• Regulatory scrutiny will remain elevated across immunology, neuroscience and aesthetics as AbbVie expands its pipeline and category exposure. Gainify
• While headline transactions in 2025 have set ambitious benchmarks, industry watchers will be scrutinising which sectors - neuroscience, oncology, or beyond are poised for further M&A activity. Pharmaceutical Technology
• Even Johnson & Johnson, which aims to become the number one company in neuroscience by 2030, axed a Phase III trial in major depressive disorder. BioSpace
• AbbVie announced it broke ground on a $195 million state-of-the-art active pharmaceutical ingredient (API) facility that will manufacture immunology, oncology and neuroscience medicines. / USA Cision PR Newswire
• Modern neuroscience has become so advanced that truly terrifying mind weapons could be created. Technocracy News

Last updated: 19 June 2026